Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Chemotherapy in combination with mogamulizumab (Mog) was approved in Japan in 2014 for untreated aggressive adult T-cell leukaemia-lymphoma (ATL), but the survival benefit remains unclear. Therefore, we retrospectively analysed clinical outcomes in 39 transplant-ineligible patients with untreated aggressive ATL at Kumamoto University Hospital between 2010 and 2021. The probability of four-year overall survival was 46.3% in the first-line Mog-containing treatment group compared to 20.6% in the chemotherapy-alone group (p = 0.033). Furthermore, this survival benefit was observed even in the elderly. In conclusion, first-line Mog-containing treatment can be a promising strategy for transplant-ineligible patients with ATL, especially in the elderly. © 2022 British Society for Haematology and John Wiley & Sons Ltd.


Takafumi Shichijo, Kisato Nosaka, Hiro Tatetsu, Yusuke Higuchi, Shinya Endo, Yoshitaka Inoue, Kosuke Toyoda, Yoshitaka Kikukawa, Toshiro Kawakita, Jun-Ichirou Yasunaga, Masao Matsuoka. Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma. British journal of haematology. 2022 Sep;198(6):983-987

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 35607839

View Full Text